Morgan Farah H, Laufgraben Marc
a Division of Endocrinology, Diabetes & Metabolism, Assistant Professor of Medicine, Cooper Medical School of Rowan University, 1210 Brace Road, Suite 107, Cherry Hill, NJ 08034, USA.
b Division Head, Division of Endocrinology, Diabetes & Metabolism, Associate Professor of Medicine, Cooper Medical School of Rowan University, Cooper University Hospital, 3 Cooper Plaza Suite 220, Camden, NJ 08103, USA.
Expert Rev Endocrinol Metab. 2013 Mar;8(2):183-193. doi: 10.1586/eem.13.3.
Cushing's syndrome is a debilitating endocrine disorder which results from hypercortisolemia. While endogenous Cushing's syndrome can be caused by an adrenocorticotrophic hormone (ACTH)-dependent or ACTH-independent mechanism, it is most often a result of excess secretion of ACTH by a corticotroph adenoma (Cushing's disease). Untreated hypercortisolemia causes significant morbidity and increased mortality due to its metabolic effects including hypertension, osteoporosis, obesity, dyslipidemia, osteoporosis and glucose intolerance. Although primary therapy is surgical, a substantial portion of patients will go on to require second-line therapies including repeat surgery, radiotherapy or drug therapy. While medical therapy for Cushing's syndrome has been limited, several new agents are being investigated. This aim of this review is to analyze and present the available options for medical management of Cushing's syndrome as well as review potential new therapies and their role in the treatment of this disorder.
库欣综合征是一种由皮质醇增多症引起的使人衰弱的内分泌疾病。虽然内源性库欣综合征可由促肾上腺皮质激素（ACTH）依赖性或ACTH非依赖性机制引起，但最常见的原因是促肾上腺皮质激素腺瘤分泌过多的ACTH（库欣病）。未经治疗的皮质醇增多症因其代谢影响，包括高血压、骨质疏松、肥胖、血脂异常、骨质疏松和葡萄糖不耐受，会导致严重的发病率和死亡率增加。虽然主要治疗方法是手术，但相当一部分患者随后将需要二线治疗，包括再次手术、放疗或药物治疗。虽然库欣综合征的药物治疗一直有限，但正在研究几种新药物。本综述的目的是分析并介绍库欣综合征药物治疗的可用选择，以及综述潜在的新疗法及其在该疾病治疗中的作用。
